Coherus Oncology (CHRS) Gross Profit (QoQ) (2019 - 2026)

Coherus Oncology (CHRS) Gross Profit (QoQ) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Coherus Oncology 200.42 Mn 33.38 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.38%
Dec 31, 2025 10.87%
Sep 30, 2025 14.45%
Jun 30, 2025 38.68%
Mar 31, 2025 -0.74%
Dec 31, 2024 49.95%
Sep 30, 2024 -60.85%
Jun 30, 2024 876.64%
Mar 31, 2024 -87.51%
Dec 31, 2023 -83.38%
Sep 30, 2023 23.61%
Jun 30, 2023 117.63%
Mar 31, 2023 -50.04%
Dec 31, 2022 205.69%
Sep 30, 2022 -79.15%
Jun 30, 2022 -3.69%
Mar 31, 2022 -17.15%
Dec 31, 2021 0.04%
Sep 30, 2021 -13.71%
Jun 30, 2021 -6.06%